Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

There are no approved pharmaceutical treatments for myopia available in the EU or the US. • Source: Shutterstock

More from Strategy

More from Therapy Areas